At-Home Starts, Procedure Economics, and Faster Devices Reshape Medtech Buying Decisions

By DripPublished

The gist

This week, device competition shifted from product features to workflow control, procedure economics, and throughput—where value is captured, not just what gets approved.

This week’s developments

Skyrizi’s At-Home Start Pushes Supervised Initiation Into the Workflow Layer

FDA’s Oct. 23, 2026 clearance for at-home Skyrizi in Crohn’s disease pushes the market one step beyond remote follow-up and even beyond the outcome-backed home-care layer: induction can now start through a device-led subcutaneous pathway at weeks 0, 2, 4, and 8, using two 360 mg/2.4 mL injections per dose instead of defaulting to clinic infusion. That matters because initiation is where the operational burden sits and where vendors can capture workflow value.

Providers now need separate pathways for IV starters and on-body injector starters, plus specialty pharmacy coordination, dose tracking, cold-chain support, teach-back training, and escalation for incomplete or failed doses. The commercial implication builds on the last few weeks’ shift from monitoring to measurable care delivery: the device is no longer the product by itself. Value is moving into the supervised start-of-therapy layer around it, where adherence, training, logistics, and exception management determine whether home initiation scales or stalls.

Where will workflow value accrue in at-home biologic initiation?

If you operate in this industry

  • Home initiation shifts value from the drug to the supervised workflow.
  • Build separate start pathways, tracking, and escalation for home vs clinic starts—or lose share to whoever owns the initiation layer.

Sources

If you sell into this industry

  • Workflow, training, and exception handling are now the monetizable layer.
  • Shift roadmap and GTM toward start-of-therapy orchestration, specialty pharmacy integration, and dose-tracking tools buyers can justify.

Sources

If you invest in this industry

  • Home-start clearance validates the workflow layer as a new profit pool.
  • Favor vendors tied to initiation, adherence, and logistics; pure device or monitoring plays look less defensible as care moves home.

Sources

LivsMed and Intuitive Push Robotics Into Procedure-Level Economics

LivsMed’s STARK and Intuitive’s 2026 antitrust settlement show the next layer of the robotics fight: economics at the procedure level. STARK is more than 50% smaller than incumbent systems and is being positioned around dexterity and deployment, with native telesurgery and wrist-like articulation up to 90 degrees in four directions; porcine demonstrations included cholecystectomy, gastrojejunostomy, and partial liver resection. That keeps the hardware race alive, but shifts attention to how easily systems can be used, scaled, and justified case by case.

Intuitive’s settlement adds a harder commercial edge: a $450 million pre-tax payment, injunctive relief, extended useful lives for selected fourth- and fifth-generation EndoWrist instruments, and pricing actions expected to cut revenue per procedure by 3% to 5% on a constant-mix basis once fully implemented, with volume-based pricing starting in 1H27. The progression from platform competition to distribution ecosystems now extends into recurring instrument and service economics. For practitioners, the key question is no longer just which robot wins placement, but which model can sustain utilization, service performance, and consumables discipline as total procedure cost comes under pressure.

How should we adapt to procedure-level economics in robotics?

If you operate in this industry

  • Robotics is now a case-by-case economics fight, not just a placement race.
  • Defend utilization and service uptime while stress-testing per-case ROI; smaller, dexterous systems may win if they lower deployment friction and cost.

Sources

If you sell into this industry

  • Procedure economics are resetting pricing power across robots and instruments.
  • Shift roadmap and GTM toward utilization, service, and consumables efficiency; buyers will reward lower per-case cost, not just better specs.

Sources

If you invest in this industry

  • Value is moving to platforms that can absorb lower per-case economics.
  • Favor scaled platform owners with pricing and service leverage; the settlement signals margin pressure and tougher returns for narrow robotics plays.

Sources

Shockwave’s C2 Aero Fly Puts Procedure Speed in the Buying Equation

J&J’s Shockwave C2 Aero Fly is pushing intravascular lithotripsy competition toward cath-lab throughput by doubling pulse delivery to 2 Hz and cutting treatment time to about 115 seconds from roughly 230. That speed story lands alongside the broader monitoring expansion already underway: remote monitoring is moving beyond diabetes into cardiac, vital-sign, sleep, and elder-safety use cases, while Sequel’s Oct. 16 FDA expansion for twiist into insulin-treated type 2 adults and Ascensia’s Oct. 10 rollout of Eversense 365 reinforce the diabetes stack as the highest-utilization segment. REMED’s KRW 15 billion equity raise plus KRW 10 billion convertible-bond financing also shows capital still favors scalable platforms with overseas distribution plans.

The progression from last week is that utilization is no longer just about recurring monitoring; it is also about how quickly a device can move through the procedure itself. For practitioners, the buying criteria are shifting from standalone performance to recurring monitoring value, workflow fit, procedure speed, and channel scale.

How should we adapt pricing and product strategy for speed-driven buying?

If you operate in this industry

  • Procedure speed is now a buying criterion, not just device efficacy.
  • If your workflow is slower, you’ll lose share to faster cath-lab tools; prove throughput gains and bundle them with monitoring value.

Sources

If you sell into this industry

  • Buyers want faster procedures plus recurring-use economics.
  • Shift the roadmap and pitch toward speed, workflow fit, and utilization; point features alone won’t win budget against platform offers.

Sources

If you invest in this industry

  • Value is moving to platforms that drive both use and throughput.
  • Favor names with recurring monitoring plus procedure-efficiency upside; standalone tools without scale or workflow pull look more fragile.

Sources

Stay ahead in Medical Devices & Tools

Get the weekly Medical Devices & Tools brief in your inbox — the developments, what they mean by vantage, and what to do next.